Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: Hold back, we are not there yet

Journal of Clinical Oncology

Volumn 25, Issue 29, 2007, Pages 4516-4518

  Baselga, José ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; DRUG SAFETY; DRUG SENSITIVITY; EDITORIAL; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; MEDICAL ONCOLOGY; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 35648956232     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.8900     Document Type: Editorial

References (14)

1. Saltz LB, Lenz HJ, Kindler HL, et al: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 25:4557-4561, 2007
2. Bukowski RM, Kabbinavar FF, Figlin RA, et al: Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cancer. J Clin Oncol 25:4536-4541, 2007
3. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997
4. Perrotte P, Matsumoto T, Inoue K, et al: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257-265, 1999
5. Viloria-Petit A, Crombet T, Jothy S, et al: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61:5090-5101, 2001
6. Ciardiello F, Bianco R, Damiano V, et al: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6:3739-3747, 2000
7. Jung YD, Mansfield PF, Akagi M, et al: Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38:1133-1140, 2002
8. Shaheen RM, Ahmad SA, Liu W, et al: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85:584-589, 2001
9. Atlas I, Mendelsohn J, Baselga J, et al: Growth regulation of human renal carcinoma cells: Role of transforming growth factor alpha. Cancer Res 52:3335-3339, 1992
10. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
11. Amgen: Amgen discontinues Vectibix treatment in PACCE trial evaluating Vectibix as part of triple combination regimen. http://www.amgen.com/media/ media_pr_detail.jsp?releaseID=977186
12. Hecht JR, Chidiac T, Mitchell E, et al: An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC): Proceedings of the 9th World Congress on Gastrointestinal Cancer. Ann Oncol 18:vii21, 2007 (abstr 0-0033)
13. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
14. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-RAS mutation status are associated with disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007